Surgical Resection for Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Virus Infection: A Chinese Multicenter Experience

H. Xing,L. Liang,C. Li,Y.-H. Zhou,W.-M. Gu,H. Wang,T.-H. Chen,F. Shen,T. Yang

DOI: https://doi.org/10.1016/j.ijsu.2020.01.107

IF: 3.842

2021-01-01

HPB

Abstract:Background and aims: There are very few studies on surgical resection for HCC in patients with HCV infection from China. Based on a multicenter database, we aimed to analyze clinical characteristics, short-term and long-term prognosis after HCC resection in Chinese patients with chronic HCV infection. Methods: The records of all patients with HCV infection who underwent curative resection for initial HCC between 2004 and 2015 were reviewed. Perioperative mortality and morbidity, long-term overall survival (OS) and recurrence-free survival (RFS) were evaluated. Results: Of the enrolled 382 patients, nearly half (46.1%) did not know their history of HCV infection before HCC diagnosis, and only 14.6% had received anti-HCV therapy before surgery. The 30-day morbidity and mortality were 44.8% and 2.9%, respectively. The 5-year OS and RFS rates were 45.0% and 34.4% respectively. Multivariable analyses showed that concurrent HBV infection, portal hypertension, tumor size > 5 cm, macrovascular and microvascular invasion, and none of postoperative anti-HCV therapy were independently associated with OS, while concurrent HBV infection, preoperative AFP level > 400ug/L, tumor size > 5 cm, multiple tumors, and macrovascular and microvascular invasion were independently associated with RFS after curative resection for HCC in patients with chronic HCV infection. Conclusions: The proportion of patients with HCV infection receiving anti-HCV therapy is low in China. Although perioperative morbidity and mortality are acceptable, the long-term outcomes are unsatisfactory, which may be related to high concurrent HBV infection rate, aggressive liver- and tumor-related characteristics, and low proportion of postoperative anti-HCV therapy.